In the context of breast cancer subtypes, genetic prediction of CD demonstrates a positive effect on estrogen receptor-positive breast cancer (ER + BC) (OR = 1.021; 95% CI: 1.002-1.040; p = 0.002) (Figure 4). The gene discussed is ESR1; the disease is breast carcinoma.